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African histoplasmosis caused by Histoplasma capsu-
latum var. duboisii is an invasive fungal infection endemic 
in central and west Africa. Most of its ecology and patho-
genesis remain unknown. H. capsulatum var. capsulatum 
is an AIDS-deﬁ  ning opportunistic infection in HIV-infected 
patients who are living in or have traveled to histoplasmo-
sis-endemic areas. In contrast, reports concerning African 
histoplasmosis during HIV infection are rare, although both 
pathogens coexist in those regions. We report 3 cases of 
imported African histoplasmosis diagnosed in France in HIV-
infected patients and a literature review on similar cases.
H
uman histoplasmosis is caused by 2 varieties of His-
toplasma. The most common variety worldwide is H. 
capsulatum var. capsulatum, which has been reported from 
many disease-endemic areas where HIV infection is preva-
lent. Histoplasmosis is more frequent in the United States 
(Ohio and Mississippi River valleys), but it is not unusual in 
other parts of the world, such as Africa (1,2). In the western 
and central regions of sub-Saharian Africa, H. capsulatum 
var. capulatum coexists with another variety, H. capsula-
tum var. duboisii, whose ecology and pathogenesis remain 
almost unknown. Cases due to H. capsulatum var. duboisii 
are scarce in Europe, and all are imported (3).
Before the era of highly-active antiretroviral therapy 
(HAART), the prevalence of H. capsulatum var. capsula-
tum infections reached up to 30% of HIV-infected patients 
in hyperendemic areas of the southeastern part of the United 
States (4). The infection occurs more often in patients with 
a CD4 count <50/mm3 and is usually disseminated. For un-
known reasons, although HIV infection and H. capsulatum 
var. duboisii coexist in Africa, this coinfection remains rare 
(5). We report 3 imported cases of the potentially emerg-
ing histoplasmosis due to H. capsulatum var. duboisii diag-
nosed in France during the course of HIV infection and a 
literature review on similar cases.
Case 1
A 37-year-old man from the Democratic Republic of 
Congo, who had lived in France since 1980, was infected 
by HIV-1 since 1987. He was admitted to the hospital in 
1992 because of a fever of unknown origin. His physical 
examination showed a left axillary tumefaction 2 inches in 
diameter. This mass had already been explored 5 months 
before. At that time, histopathologic examination disclosed 
a necrotizing lymphadenitis with epithelioid cells but with-
out caseum. No microorganism was seen after Ziehl, pe-
riodic acid–Schiff, and Grocott stainings, but culture was 
not performed. When the patient was hospitalized in 1992, 
laboratory tests showed an erythrocyte sedimentation rate 
of 104 mm, ﬁ  brin 4.5 g/L, C-reactive protein 74 mg/L, 
and a CD4 count of 100/mm3 (9%). The adenopathy was 
surgically removed. Histopathologic examination showed 
necrosis and large yeasts, and culture grew Histoplasma 
sp. on day 12. Anti-Histoplasma antibody detection was 
negative. No other lymph node, bone, skin, or bone marrow 
involvement was found.
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Itraconazole treatment was started (400 mg/d), but it 
was switched to amphotericin B (1 mg/kg/d) after 3 weeks 
because local symptoms persisted. The total dose of ampho-
tericin B was 1,200 mg. Itraconazole (400 mg/d) was then 
restarted for 1 year. The clinical course was satisfactory, 
so itraconazole was lowered to 200 mg/d for 3 years. The 
patient died in 1995 of HIV-related encephalitis despite an-
tiretroviral therapy, including nucleoside reverse transcrip-
tase inhibitors, without recurrence of histoplasmosis.
Case 2
A 41-year-old man from the Democratic Republic of 
Congo, who had lived in France since 1981, was infected 
by HIV-1 in 1994. He received AZT (3′-azido-3′-deoxythy-
midine) and diethyldithiocarbamate (ddC) when Pneumo-
cystis  jiroveci pneumonia was diagnosed in December 
1995. Despite the introduction of HAART in 1996 (AZT, 
lamivudine [3TC], and ritonavir), his CD4 count remained 
<50/mm3. In mid-1996, nodular cutaneous lesions, a right 
cervical adenopathy, and a right Bell’s palsy developed. 
Direct examination of the lymph node showed numerous 
yeasts with a typical lemon shape and a narrow budding, 
suggestive of H. capsulatum var. duboisii. The culture 
grew Histoplasma sp.
The patient did not respond to itraconazole (400 mg/d). 
After 1 month, he was given conventional amphotericin B 
(1 mg/kg/d); severe renal insufﬁ  ciency developed within 8 
days. Treatment was switched to liposomal amphotericin B 
(3 mg/kg/d) with a dramatic improvement of the symptoms 
and partial regression of the renal insufﬁ  ciency. Immune 
reconstitution inﬂ  ammatory syndrome also developed; its 
characteristics were reported previously (6). After 1 month, 
treatment was switched to itraconazole, 400 mg/d, for long-
term therapy. Because of a persistent low CD4 count de-
spite undetectable viral load, the patient beneﬁ  ted from 
several courses of interleukin-2 (IL-2) therapy, which al-
lowed a marked and sustained increase of the CD4 count. 
Itraconazole was stopped in 1996. His condition remains 
stable 11 years later, and no recurrence of histoplasmosis 
has been observed.
Case 3
A 2-year-old girl from the Democratic Republic of 
Congo was referred to the hospital in June 2001 for a fe-
ver of unknown origin. (She arrived in France in 2001 at 
the age of 18 months.) Investigations showed Escherichia 
coli pyelonephritis. HIV-1 serologic test results were posi-
tive, and her CD4 count was 45/mm3. HAART was started 
quickly, combining AZT, 3TC, and nelﬁ  navir. This treat-
ment resulted in a decrease in, but not elimination of, the 
viral load and a CD4 count <200/mm3 despite appropriate 
nelﬁ  navir serum concentrations.
In August 2001, a frontal swelling appeared, associ-
ated with fever and generalized weakness. Direct examina-
tion of a skin biopsy specimen showed large, lemon-shaped 
yeasts suggestive of H. capsulatum var. duboisii. Culture of 
this specimen grew Histoplasma sp. Diffuse bone involve-
ment (several lytic lesions of the right humerus, left ulna, 
both tibias, right ﬁ  bula) was found on radiographs. Culture 
of the buffy coat was concomitantly positive for Fusarium 
verticillioides. No involvement of the lungs or lymph nodes 
was found.
Treatment with liposomal amphotericin B was started 
but switched to itraconazole after 1 month. Fever relapsed 
shortly thereafter, as well as the facial tumefaction. Radio-
graphic examination showed several lesions of the skull, 
and a bone biopsy demonstrated large yeasts on direct ex-
amination. Amphotericin B was restarted for 4 months. The 
patient’s status improved dramatically, and the treatment 
was switched to ﬂ  uconazole until September 2003. She did 
not experience any relapse, and antifungal prophylaxis was 
discontinued because of the improvement of her immuno-
logic status (CD4 count >200/mm3 and undetectable viral 
load). In July 2007, she is doing well with a CD4 count of 
700/mm3 and a still-undetectable viral load.
Discussion
H. capsulatum var. duboisii is also known as African 
histoplasmosis because it has only been described on that 
continent, mostly in central and western Africa. The preva-
lence of histoplasmosis due to variety duboisii has not been 
established in countries in these regions in HIV-negative 
patients. Fewer than 300 cases are reported in the litera-
ture (7). The reason it remains rare, despite the major HIV 
pandemic in Africa, is unknown. Potential explanations 
are that patients die from other causes before histoplasmo-
sis develops (8) or that variety capsulatum is more viru-
lent than variety duboisii. This situation is reminiscent of 
Cryptococcus gattii and C. neoformans. C. gattii is rarely 
identiﬁ  ed in HIV-infected patients, in contrast with C. neo-
formans, whereas both are present in the environment in 
countries where the prevalence of HIV infection is high 
(9). However, variety capsulatum is frequent in Africa. No 
data on the relative frequency of those 2 varieties has been 
published. Skin reaction to histoplasmin in histoplasmosis-
endemic areas showed a 3% prevalence (10), but variety 
capsulatum and variety duboisii were not able to be dif-
ferentiated. Higher prevalence (≈35%) was found in rural 
populations, especially among farmers, traders, and cave 
guides (11). Histoplasmosis due to variety duboisii may be 
misdiagnosed in those areas because of physicians’ lack of 
awareness.
The pathogenesis of African histoplasmosis remains 
unclear. The main route of acquisition could be airborne 
contamination from the soil, rarely direct inoculation. Vari-
ety duboisii is classically associated with cutaneous lesions 
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(nodules, ulcers) and osteolytic bone lesions, especially af-
fecting the skull, ribs, and vertebrae (Table 1) (12,13). His-
topathologic examination shows granuloma with necrosis 
and suppuration. Disseminated disease is not uncommon 
and can involve every organ; however, the heart and central 
nervous system are unusual locations. A total of 17 cases 
have been reported thus far among HIV-infected patients, 
including the 3 cases described here (14–19). An additional 
case has been reported, but without detailed description, 
in a Ugandan patient diagnosed in Japan (20). Among the 
well-described cases (Table 1), most involved patients with 
poor immunologic status (mean CD4 count 55/mm3), which 
also occurs with histoplasmosis due to variety capsulatum 
(21). Most patients had disseminated infections, and only 
4 patients died. The prognosis of disseminated infection 
in this context is close to the 20% mortality rate reported 
for disseminated histoplasmosis due to variety capsulatum 
among AIDS patients (21), but the few number of cases 
does not allow us to extrapolate the mortality rate related 
to variety duboisii.  Epidemiologic information, clinical 
manifestations, and outcomes of immunocompetent versus 
HIV-infected patients infected with variety duboisii are 
compared in Table 2 (13). These data conﬁ  rm the tropism 
of variety duboisii for lymph nodes, skin, and bones. It is 
noteworthy that the disease is often located in the lungs in 
HIV-negative patients, whereas HIV-infected patients have 
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Table 1. Description of HIV-infected patients with histoplasmosis due to Histoplasma capsulatum var. duboisii*
Case







1 20 F Congo Skin lesions  NR Skin – AmB 1 mg/kg/d, 
Itr 300 mg/d 
Relapse
2 44 M Congo Skin lesions, weight 
loss, lymph nodes, 
peritonitis
NR Skin, pus  – Ketoconazole 600 
mg/d, AmB, Itr 
300 mg/d 
Relapse
3 41 M Congo Skin lesions, weight 
loss, lymph nodes, 
hepatomegaly, 
splenomegaly 
NR Skin – AmB Death








5 28 M DRC Fever, skin lesions, 
lymph nodes, weight 
loss, bone lesions 
NR Skin Skin Ketoconazole 600 
mg/d
NR






Itr 400 mg/d 
No relapse 
7 29 M Liberia Skin lesions  NR Skin Skin Itr 200 mg/d  NR
8 43 F Guinea-
Bissau
Fever, weight loss, 
anemia, abdominal 
pain
68 Colon – Itr 400 mg/d  No relapse 
9 30 M Nigeria Fever, skin lesions, 
lymph nodes, anemia 
2 Skin Skin AmB 1 mg/kg/d, 
Itr 400 mg/d 
Relapse








AmB No relapse 




– AmB 1 mg/kg/ 
48 h 
No relapse 
12 30 M Côte
d’Ivoire




– Itr 400 mg/d  No relapse 
13 50 F Nigeria Skin lesions, bone 
lesions
NR Skin, bone – Fluconazole 100 
mg/d
No relapse 
14 45 M Ghana Fever, weight loss, 
splenomegaly 
24 Blood – AmB 0.7 mg/kg/d  Death
15 37 M DRC Fever, lymph nodes  100 Lymph 
nodes
– Itr 400 mg/d  Death







Itr 400 mg/d 
No relapse 
17 2 F DRC Fever, skin lesions, 
bone lesions 
45 Skin, bone Skin Liposomal AmB, 
fluconazole
No relapse 
*NR, not reported; AmB, amphotericin B deoxycholate; Itr, itraconazole; DRC, Democratic Republic of Congo; ABLC, amphotericin B lipid complex. 
†Cases 1–14 are from the literature review; cases 15–17 are personal cases; see text. SYNOPSIS
substantially more disseminated disease. The latter ﬁ  nding 
may be explained by immunodepression, poor access to the 
healthcare system for HIV-infected persons in Africa, and 
late diagnoses of histoplasmosis. 
Despite its rarity, African histoplasmosis should be kept 
in mind as a diagnosis in Africa-born patients or travelers to 
sub-Saharan West and central Africa who have compatible 
signs or symptoms, even if they are HIV-infected, because 
the saprophytic phase of this dimorphic fungus should be 
manipulated in a Biosafety Level 3 cabinet. The laboratory 
diagnosis is performed by direct examination and culture. 
Cultures of tissue samples or body ﬂ  uids are made onto Sa-
bouraud dextrose agar, incubated at 25°C; incubation could 
be prolonged for up to 6 weeks. The success rate depends 
on the extent of infection, the source of the sample, and the 
prompt processing of the sample.
In addition to differences in clinical manifestations and 
epidemiology, the 2 varieties can be easily distinguished on 
observation of the yeast phases present in infected fresh 
or ﬁ  xed tissues, whereas the saprophytic phase is identical. 
Variety capsulatum presents as small (3-μm) oval yeasts 
free or inside histocytes or macrophages (Figure 1), where-
as yeasts of variety duboisii are large (7–15 μm), globose 
to ovoid, thick-walled, and typically lemon-shaped with a 
narrow budding (Figure 2). They are often seen in the cyto-
plasma of giant cells (1).
Diagnoses such as cryptococcosis and blastomycosis 
can be easily ruled out by direct examination or histopathol-
ogy, but blastomycosis is unlikely in central and western 
African patients (22). The differential diagnosis is rarely 
difﬁ  cult with cryptococcosis because of the shape and size 
of yeasts, presence of capsule, and lack of inﬂ  ammation in 
the surrounding tissue. In any event, cryptococcal antigen 
testing and culture will easily ascertain the diagnosis.
Antigen detection in serum and urine is a sensitive test 
but has been developed for the variety capsulatum. It is val-
idated in HIV-infected patients with disseminated diseases 
(8,23,24). H. duboisii is a cause of false-positive test results 
for antigen detection in urine. Antibody detection is use-
ful for the retrospective diagnosis of histoplasmosis caused 
by variety capsulatum. Since variety duboisii antigens may 
cross-react with those of the variety capsulatum, serologic 
tests are potentially useful for diagnosis of African histo-
plamosis.
Although some PCR assays have been developed, they 
are not yet routinely used (25). Real-time and semi-nested 
PCR seem promising for the diagnosis of histoplasmosis 
due to variety capsulatum in blood and tissue samples (26–
28). No PCR has yet been developed for variety duboisii, 
but a speciﬁ  c PCR assay could be helpful for this underdi-
agnosed disease.
Treatment of African histoplasmosis can be extrapo-
lated from the guidelines of the Infectious Diseases Society 
of America established for histoplasmosis due to variety 
caspulatum (29). No clinical trial or efﬁ  cacy studies have 
been performed for histoplasmosis due to variety duboi-
sii, but as mortality rates are similar for the 2 species with 
the same management, the guidelines can be extrapolated 
to African histoplasmosis. In patients with AIDS, recom-
mended therapy includes an intensive phase of 3 months 
with amphotericin B replaced by itraconazole (400 mg/d) 
for the severe forms, or itraconazole alone (600 mg/d for 3 
days, then 400 mg/d) for mild forms. Fluconazole (800 mg/
d) can be an alternative, but it has lower efﬁ  cacy and a high-
er recurrence rate with isolates harboring higher MICs (30). 
Moreover, new azoles such as voriconazole require careful 
biologic and clinical monitoring when used for treating his-
toplasmosis in HIV-infected patients because of increased 
risk for in vitro resistance, especially in patients who had 
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Table 2. Comparison of clinical and microbiologic findings of HIV-




(n = 17) 
HIV negative 
(n = 20) 
Age, y (range)  35 (2–65)  34 (8–62) 
Sex (M:F)  12:5 19:1
Visceral localizations 
 Lymph  nodes  53 65
 Skin  59 40
 Bones  18 25
 Lungs  0† 35†
 Gastrointestinal  12 5
 Disseminated  85† 55†
Clinical manifestations 
 Fever  58† 15†
  Weight loss, asthenia, anorexia  54 30
 Respiratory  symptoms  0 20
 Hepatosplenomegaly  12 15
Diagnosis sites 
 Lymph  nodes  24 45
 Skin  48 35
 Bone  marrow  18 0
 Bone  12 5
 Gastrointestinal  6 5
 Pus  6 25
 Lung  0† 25†
Mycologic diagnosis 
 Direct  examination  100 40
 Culture  64 65
 Blood  culture  12 0
Treatment 
 Amphotericin  B  66 80
 Ketoconazole  12 35
 Itraconazole  64 20
 Fluconazole  12 0
Outcome
 Relapse  12 40
 Death  24 5
*Except where indicated, all values are percentages. HIV-negative patients
are from Dupont et al. (13). 
†p<0.05. African Histoplasmosis in HIV Patients
ﬂ  uconazole (31). Nothing is known, however, about devel-
opment of resistance for variety duboisii. Managing AIDS 
by HAART is an essential part of the treatment. The avail-
ability of HAART in Africa is increasing, but it may be 
absent in areas where histoplasmosis is endemic. This is a 
real concern for optimal management of such patients.
Maintenance therapy with itraconazole (200 mg or 400 
mg/d) is recommended. Fluconazole (400 mg/d) should be 
avoided because of its reduced capacity to prevent relapses. 
However, as for many other opportunistic infections, main-
tenance therapy can be discontinued if the immunologic 
status of the patient improves, as described for case-patient 
3. This patient’s prophylaxis was stopped 3 years ago, and 
she experienced no relapse and her CD4 count has always 
been >200/mm3. The stability of immune improvement has 
to be conﬁ  rmed for several months before prophylaxis is 
stopped (32). Recent data suggest that the risk for relapse 
is rare after 12 months of treatment with a sustained im-
munologic improvement (CD4 >150/mm3) (33). However, 
in our experience based on the management of 20 cases 
of histoplasmosis due to variety duboisii in patients con-
sidered immunocompetent (13), relapses may be observed 
several years after the ﬁ  rst episode. Thus, prolonged fol-
low-up is mandatory for every patient with histoplasmosis 
due to variety duboisii.
Since HAART was introduced, the clinical and immu-
nologic conditions of HIV-infected patients have dramati-
cally improved, but physicians should now be aware of im-
mune reconstitution inﬂ  ammatory syndrome (IRIS) (34). 
As for many pathogens, both varieties of H. capsulatum can 
induce IRIS in HIV-infected patients, as recently reported 
by our group (6). The importance of the inﬂ  ammatory reac-
tion during IRIS contrasts with the mild one observed in 
the initial phase of the disease in severely immunocompro-
mised patients and may require speciﬁ  c treatment.
Thus, histoplasmosis due to variety duboisii in HIV-
infected patient remains a rare clinical entity but diagnosis 
should not be discounted because of the HIV status of the 
patient. Physicians working in Africa should be aware of H. 
capsulatum var. duboisii as a potentially emerging infec-
tion in HIV-infected patients.
Dr Loulergue is an infectious diseases fellow attending the 
Infectious Diseases Department of Necker-Enfants Malades Uni-
versity Hospital, Paris, France. His research interests include in-
fectious diseases in immunocompromised hosts and development 
of vaccines.
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